Saturday 24 October 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
2
Average plausibility
76%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
RegionAllGlobalAfricaNorth AmericaSouth AmericaAsia-PacificEuropeMiddle East
TopicAllPoliticsConflict & SecurityBusinessScienceHealth
01Conflict & SecurityGlobal

BBC reports AI-discovered flaws prompted global cybersecurity response

A PHP-focused report describes long-hidden programming flaws, but supplies little technical evidence.

The BBC reports that AI uncovered long-hidden programming flaws, triggering a rare global cybersecurity response. Its headline links the security scramble to PHP, but the supplied summary does not identify the vulnerabilities or affected systems.

What holds up

  • ✓The BBC explicitly reports AI involvement in uncovering programming flaws.
  • ✓The item describes the resulting cybersecurity response as global.

What doesn't yet

  • ?No vulnerability identifiers, technical advisories or affected versions are supplied.
  • ?The summary does not explain AI's precise role or establish whether the flaws were exploited.

Ask before you share

  • →Which technical advisories identify affected systems and available fixes?
  • →Were the flaws exploited, or was the response precautionary?

Sources & original reporting

  1. [1]BBC News · Published 23 Oct 2026 · bbc.co.uk
02HealthGlobal

Personalized cancer vaccine trial reports reduced recurrence risk

Two outlets describe favorable trial results, but the excerpts omit the effect size and study methods.

The BBC reports that a personalized cancer vaccine reduced the risk of disease returning in a major trial. The Guardian describes a bespoke mRNA vaccine trial showing a significant reduction in the risk of melanoma recurrence or death.

What holds up

  • ✓Both outlets report favorable clinical trial findings for a personalized cancer vaccine.
  • ✓Both accounts describe reduced recurrence risk, with The Guardian specifying melanoma and an outcome including death.

What doesn't yet

  • ?Neither excerpt supplies trial size, comparator, follow-up duration, effect size or safety findings.
  • ?Descriptions of a turning point or foundational shift reflect researchers' interpretations, not proof of broad clinical benefit.

Ask before you share

  • →What were the absolute risk reduction, comparator and follow-up period?
  • →Which patients were studied, and what adverse effects occurred?

Sources & original reporting

  1. [1]BBC News · Published 23 Oct 2026 · bbc.co.uk
  2. [2]The Guardian · Published 23 Oct 2026 · theguardian.com